Erratum: Corrigendum: Whole–genome characterization of chemoresistant ovarian cancer
Suzanne Manning(Vanderbilt University), Charlotte S. Wilhelm-Benartzi(Cardiff University), Gisela Mir Arnau(Peter MacCallum Cancer Centre), Anne Hamilton(Royal Women's Hospital), Jan Pyman(Royal Women's Hospital), Walid J. Azar(Peter MacCallum Cancer Centre), Timothy Semple(The University of Melbourne), Greg Young(Victorian Institute of Forensic Medicine), Michael Friedländer(Prince of Wales Hospital), George Au‐Yeung(The University of Melbourne), Kathryn Alsop(Peter MacCallum Cancer Centre), Ann‐Marie Patch(QIMR Berghofer Medical Research Institute), Kelly Quek(South Australian Health and Medical Research Institute), Ehsan Nourbakhsh(Shahid Beheshti University of Medical Sciences), Prue A. Cowin(Broad Institute), Elizabeth L. Christie(Peter MacCallum Cancer Centre), Edward Curry(Age UK), Joshy George(Jackson Laboratory), Catherine J. Kennedy(The University of Sydney), Joy Hendley(Peter MacCallum Cancer Centre), Karin S. Kassahn(South Australia Pathology), Sián Fereday(Peter MacCallum Cancer Centre), Mark Shackleton(Australian Research Council), Linda Mileshkin(Peter MacCallum Cancer Centre), Felicity Newell(QIMR Berghofer Medical Research Institute), Timothy P. Holloway(Peter MacCallum Cancer Centre), Yoke-Eng Chiew(The University of Sydney), Paul Waring(Royal Women's Hospital), Paul R. Harnett(The University of Sydney), Craig Nourse(Champalimaud Foundation), Stephen H. Kazakoff(QIMR Berghofer Medical Research Institute), Kate Strachan(The University of Melbourne), Dale W. Garsed(Peter MacCallum Cancer Centre), Richard W. Tothill(The University of Melbourne), Kátia Nones(QIMR Berghofer Medical Research Institute), Dariush Etemadmoghadam(Peter MacCallum Cancer Centre), Thomas J. Mitchell(University of Cambridge), Ivon Harliwong(The University of Queensland), Peter J. Bailey(Cambridge University Hospitals NHS Foundation Trust), Heather Thorne(University of Melbourne), Michael C. Quinn(New South Wales Department of Health), David K. Miller(The University of Queensland), Stephen Cordner(Australian Regenerative Medicine Institute), Patricia J. O’Brien(Boston Children's Hospital), Huei San Leong(Peter MacCallum Cancer Centre), Jillian A. Hung(Millennium Institute), Nadia Traficante(The University of Melbourne), Jodie Leditschke(Victorian Institute of Forensic Medicine)
Cited by 25
Related Papers
Pan-cancer analysis of whole genomes
|Nature|2020|3.3k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k